Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We aimed to evaluate the efficacy and safety of surgical resection or chemotherapy following serplulimab plus platinum-containing dual induction therapy for stage II-IIIB (N2) LS-SCLC

Trial Details

NCT ID
NCT06911606
Phase
PHASE2
Sponsor
Guangdong Provincial People's Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • 4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Voluntarily participate in clinical research and sign written informed consent
  • Male or female patients aged 18-75 years old (including the critical value)
  • Histologically or cytologically confirmed SCLC
  • Clinically diagnosed as IIB-IIIB ( N2) stage (AJCC 8th edition cancer staging)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →